Navigation Links
IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
Date:5/15/2008

e program had documented diagnosis of high grade osteosarcoma with relapsed or recurrent disease (locally or metastatic) with resectable or not completely resectable disease, or who are unable to complete recommended chemotherapy due to toxicity.

L-MTP-PE (2 mg/m2 IV over 1 hour) was administered twice a week for 12 weeks followed by once a week for 24 weeks. In addition, some patients in the program were also treated with other agents including aerosol recombinant granulocyte monocyte colony stimulating factor (GM-CSF) an immune stimulating agent (n=20), ifosfamide (n=4), and/or gemcitabine (n=2).

Results to date are as follows:

-- Nine patients are alive with disease.

-- Nine patients have no evidence of disease.

-- Nine patients have died.

-- There are two patients for whom the status is unknown.

Treatment with L-MTP-PE combined with other agents including aerosol GM- CSF was generally well tolerated. Patients treated with chemotherapy had no unexpected toxicities and toxicity from L-MTP-PE infusions was minimal. There were no reports of grade 3 or 4 drug-related toxicities with the exception of fever grade 3 and flu-like symptoms with the first dose. This was prevented with ibuprofen and acetaminophen after subsequent doses. One patient developed pleural and pericardial effusion that was possibly L-MTP-PE and/or GM-CSF related and the patient was removed from the study.

In March, the Company announced that it had formalized a clinical protocol with the FDA, which provides L-MTP-PE to eligible, high-risk osteosarcoma patients through a compassionate access study. The compassionate access study is being conducted initially at M. D. Anderson and Memorial-Sloan Kettering Cancer Center in New York.

"Patients are our first priority and we are committed to providing L-MTP- PE to those who desperately need treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "The potentia
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
3. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
4. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
5. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
10. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
11. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... YORK , LONDON , ... , May 20, 2013 ... of Osteoarthritis and Preference for Minimally Invasive Procedures to ... landscape, and market trends for the six arthroscopy device ... (FMSs), arthroscopy implants, arthroscopy radio frequency systems, and arthroscopy ...
(Date:5/20/2013)... announced today the presentation of results from a new ... among diabetic patients in the U.S. than previously recognized. ... both type 1 and type 2 diabetes, but this ... common type 2 disease. Lee ... Medicine at Harvard Medical School and Director of the ...
(Date:5/20/2013)... CHICAGO, Ill. , May 20, 2013 /PRNewswire/ ... the initiation of a Phase 3 clinical study ... to assess the effects of the investigational compound ... progression of kidney disease in patients with stage ... type 2 diabetes.  SONAR is a large, multinational, ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... Medical Tactile, Inc. and Valentus Medical Technologies, Inc. ... , Canada , has signed a partnership agreement with Medical Tactile, ... SureTouch™ , the non-invasive digital breast imaging technology, worldwide, with the ... , , ...
... July 13 Amira Pharmaceuticals, Inc. today announced that the ... Activating Protein (FLAP) Inhibitors," which includes coverage of Amira,s AM103 and ... , , ... , Amira and GlaxoSmithKline (GSK) entered into a worldwide exclusive agreement ...
Cached Medicine Technology:Partnership Brings Breast Image Documentation Technology to Women Around the World 2Amira Announces AM103 and AM803 Patent Grant in the United Kingdom 2
(Date:5/20/2013)... new Canadian study has uncovered an apparent gender bias ... men to get trauma center care following a severe ... services in general have been recognized for some time, ... the treatment of severe injuries in trauma centers," study ... Sciences Centre and the University of Toronto, said in ...
(Date:5/20/2013)... in Sweden have mapped the significance of heredity ... have previously examined whether different forms of the ... heart disease, ischemic stroke, peripheral arterial disease and ... and parents have suffered different types of cardiovascular ... highest for atherosclerosis of the aorta followed by ...
(Date:5/20/2013)... Plains, NY (PRWEB) May 20, 2013 ... firm of Levy Phillips & Konigsberg LLP ... Street in White Plains, New York. LPK will better ... in the Hudson Valley, including Westchester, Putnam, Rockland, Orange, ... helping families affected by asbestos-related diseases throughout New York, ...
(Date:5/20/2013)... as a consequence of diabetic foot ulcer that does ... this situation are very limited. In his doctoral thesis ... Department of Medical Biochemistry and Biophysics at Ume University ... may completely change the lives of millions of patients. ... chronic wounds that largely impair the quality of life ...
(Date:5/20/2013)... May 20, 2013 The producers of ... to the essentials of home schooling. It will educate viewers ... need to assist children in reaching educational goals. Most homes ... basic needs in education. Instructors can send tests to state ... the Web. The celebrity-hosted segment is a top-notch guide for ...
Breaking Medicine News(10 mins):Health News:Women Less Likely to Get Trauma Center Care After Injury: Study 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:Editions TV Presents a Home School Essentials Segment 2
... Support NIH Information Sharing and Collaboration ServicesCHANTILLY, Va., ... region,s leading providers of government professional technical solutions, ... by the National Institutes of Health (NIH) for ... February 18, 2009, covers a one year period ...
... 25 AdaptaVan, LLC has announced partnerships with ... of its customized wheelchair-accessible vans throughout ... Emmett Koelsch Coaches, Inc. of Oregon City, Ore.; ... Conn.; Superior Chevrolet, Inc. of Cincinnati, Ohio; Autotronics ...
... Cancer Center have developed an assay that may be ... a predisposition to cancer. , The study, published in ... done in yeast and mammalian cells. , Cancer cells ... Robert Schiestl, have discovered a mechanism that switches on ...
... LONDON, March 25 Clinica - the world,s leading medical,technology ... state of,asbestos regulation in the UK, in light of discrepancies ... Westminster. , On the day of ... latest developments in Clinica,s investigation into the extent,of the problem ...
... March 25 Abbott ( NYSE: ABT ) will announce ... before the market opens.The announcement will be followed by a ... Central time (9 a.m. Eastern), and will be accessible through ... An archived edition of the call will be available after ...
... Physicians Practice and Rose Medical Center have joined forces ... time to devote to patient care. This new partnership ... the Denver Metro Area better handle the cumbersome and ... new alliance, Rose Medical Center will use Physicians Practice,s ...
Cached Medicine News:Health News:NIH Awards Blanket Purchase Agreement (BPA) to Citizant 2Health News:AdaptaVan, LLC Expands National Availability of Wheelchair-Accessible Vans 2Health News:Discovery may result in new test to determine predisposition to cancer 2Health News:Discovery may result in new test to determine predisposition to cancer 3Health News:Westminster Safety Disagreement Highlights Risk in Schools 2Health News:Westminster Safety Disagreement Highlights Risk in Schools 3Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 2Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 3
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: